Adult patients ( 18 years of age ) with a first recurrence of a glioblastoma after temozolomide chemoradiotherapy were randomly allocated by a web-based program to treatment with oral lomustine 110 mg/m ( 2 ) once every 6 weeks , intravenous bevacizumab 10 mg/kg once every 2 weeks , or combination treatment with lomustine 110 mg/m ( 2 ) every 6 weeks and bevacizumab 10 mg/kg every 2 weeks .